The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

(2020) W. Timothy Garvey et al.   DIABETES CARE

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

(2020) Juan Pablo Frias et al.   DIABETES OBESITY & METABOLISM

357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11

(2020) JUAN P. FRIAS et al.   DIABETES

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

(2019) Lærke S. Gasbjerg et al.   DIABETES

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

(2019) V. R Aroda et al.   DIABETES & METABOLISM

1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM

(2019) KENJI OHWAKI et al.   DIABETES

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Searching for the physiological role of glucose-dependent insulinotropic polypeptide

(2016) Jens Juul Holst et al.   Journal of Diabetes Investigation

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

(2016) Michael A Nauck et al.   Lancet Diabetes & Endocrinology

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies

(2013) S. Calanna et al.   DIABETES CARE

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

(2013) S. Calanna et al.   DIABETOLOGIA

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes

(2013) Mikkel B. Christensen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis

(2012) Su-Jin Kim et al.   PLoS One

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

(2011) Asger Lund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans

(2011) M. Christensen et al.   DIABETES

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

(2011) N. Mentis et al.   DIABETES

Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

(2009) C. Daousi et al.   CLINICAL ENDOCRINOLOGY

Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

(2009) C. W. Chia et al.   DIABETES

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS